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Pyridoxamine inhibits early renal disease and dyslipidemia in process known as the Maillard or browning reaction.
the streptozotocin-diabetic rat. This reaction begins with adduction of a reducing sugar
Background. Nonenzymatic reactions between sugars or lip- to an amino group in protein, typically the ε-amino groupids and protein and formation of advanced glycation and lipoxi-
of a lysine residue, to form a Schiff base (imine), whichdation end products (AGE/ALEs) contribute to the chemical
then rearranges to an Amadori compound (ketoamine),modification and cross-linking of tissue proteins with age. Ac-
celerated formation of AGE/ALEs during hyperglycemia is such as fructoselysine. The Amadori product is a precur-
implicated in the development of diabetic complications. In sor to AGEs, which are a more permanent, irreversible
this study, we examined the effect of the AGE/ALE inhibitor modification of proteins. According to the AGE hypoth-pyridoxamine on chemical modification and cross-linking of
esis [1, 2], the increased rate of chemical modificationcollagen and development of renal disease in the streptozo-
tocin-diabetic rat. and cross-linking of tissue proteins during hyperglycemia
Methods. Diabetic rats were treated with pyridoxamine; par- compromises the structure and function of proteins and
allel experiments were conducted with aminoguanidine, the contributes to the development of chronic complications
prototype AGE inhibitor. Progression of renal disease was
in diabetes. The accumulation of AGEs in collagen, aevaluated by measurements of albuminuria and plasma creati-
long-lived protein in the extracellular matrix, is thoughtnine concentration. Plasma triglycerides, cholesterol, lactate
and pyruvate were measured by enzymatic assays, and AGE/ to effect changes in elasticity, ionic charge, thickness and
ALEs in skin collagen by HPLC and GC-MS assays. turnover of basement membrane components, setting
Results. Pyridoxamine significantly inhibited the increase in the stage for development of diabetic renal, retinal andalbuminuria, plasma creatinine, hyperlipidemia and plasma lac-
vascular disease.tate/pyruvate ratio in diabetic rats, without an effect on blood
glucose or glycated hemoglobin. AGE/ALEs, fluorescence and Reactive carbonyl and dicarbonyl compounds derived
cross-linking of skin collagen increased approximately twofold from sugars are intermediates in the formation of AGEs,
in diabetic versus control rats after seven months of diabetes. and oxygen, redox active transition metal ions and reac-
Pyridoxamine caused a significant (25 to 50%) decrease the
tive oxygen species are recognized as catalysts of AGEAGE/ALEs, carboxymethyllysine and carboxyethyllysine, cross-
formation [3]. The precise chemical origin of specificlinking and fluorescence in skin collagen of diabetic rats, but
did not affect pentosidine. AGEs is not always clear. Some AGEs, such as pentosi-
Conclusions. Pyridoxamine inhibits the progression of renal dine, are clearly derived from carbohydrates, but may
disease, and decreases hyperlipidemia and apparent redox im- be formed from glucose, ascorbate, 3-deoxyglucosonebalances in diabetic rats. Pyridoxamine and aminoguanidine
or other sugars in vivo [4]. The major AGEs, includinghad similar effects on parameters measured, supporting a
the lysine adducts Nε-(carboxymethyl)lysine (CML) andmechanism of action involving AGE/ALE inhibition.
Nε-(carboxyethyl)lysine (CEL), and the imidazolium
crosslinks glyoxal-lysine dimer (GOLD) and methylgly-Advanced glycation end products (AGE) are formed
oxal-lysine dimer (MOLD), may be formed from early,by chemical reaction of carbohydrates with protein in a
protein-bound intermediates in the Maillard reaction,
such as the Schiff base or Amadori compound. However,
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they also may be formed directly from glyoxal or meth-end-product, aminoguanidine, hyperglycemia, albuminuria, Nε-(car-
boxymethyl)lysine (CML), collagen, dyslipidemia. ylglyoxal, which in turn may be derived by either chemi-
cal or enzymatic reactions from both carbohydrates andReceived for publication June 8, 2001
lipids [4, 5]. Thus, the increase in CML and CEL inand in revised form October 18, 2001
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teins in the vascular wall. In this case, CML and CEL and non-diabetic renal disease [17–21], our results sug-
are more properly described as advanced lipoxidation gest that the renoprotective effects of PM may derive
end-products (ALE) [5]. In the absence of firm evidence from both its AGE/ALE inhibitory and its lipid-lowering
on their origin, even during hyperglycemia in diabetes, activities. The relationship between these two activities
these compounds should be referred to as AGE/ALEs, of PM is also discussed.
that is, products that may be derived from reactions of
carbohydrate and/or lipids with proteins.
METHODSA number of compounds have been described as AGE
Materialsinhibitors, based on their inhibition of AGE formation
during incubation of proteins with glucose in vitro. These Female Sprague-Dawley rats (8 weeks old, 150 g)
inhibitors vary widely in structure, the common theme were obtained from Harlan Corp. (Indianapolis, IN,
being their nucleophilicity or reactivity with reactive car- USA). PM · (HCl)2, AG hemisulfate, STZ and clinical
bonyl intermediates in AGE formation. Aminoguani- assay kits were obtained from Sigma Chemicals Inc. (St.
dine (AG), the prototype AGE inhibitor, inhibited the Louis, MO, USA).
increase in fluorescence and cross-linking of aortic colla-
gen in diabetic rats [6]. In subsequent studies, AG and Animal studies
the related compounds, OPB-9195 (2-isopropylidenehy- Rats were treated according to the guidelines of the
drazono-4-oxo-thiazolidin-5-yl-acetanilide) and 2,3-dia- Institutional Animal Care and Use Committee of the
minophenazine retarded the development of retinal, vas- University of South Carolina. Diabetes was induced by
cular and renal pathology in diabetic animals [7–9]. a single tail vein injection of 45 mg/kg of STZ in 0.1 mol/L
Protective effects of these inhibitors were associated with sodium citrate buffer, pH 4.5. Non-diabetic animals were
a decrease in AGEs in serum proteins measured by en- sham injected with buffer only. Diabetes was confirmed
zyme-linked immunosorbent assay (ELISA) [10], or in by measuring blood glucose levels at two and three days
lens proteins [11] or tissues collagens [8, 9, 12] by immu- after the STZ-injection. Animals with plasma glucose
nohistochemistry. In no instance have the immunohisto- higher than 16 mmol/L were classified as diabetic. The
chemical observations been confirmed by direct chemical diabetic rats were divided randomly into an untreated
analysis for specific AGEs in tissue proteins.
diabetic group (diabetic control; N  12) and two dia-
Hudson and colleagues recently described a new class
betic treatment groups, receiving either PM (diabetic 
of post-Amadori AGE inhibitors, termed Amadorins,
PM; N  13) or AG (diabetic  AG; N  12) at 1 g/Lwhich block the formation of AGEs from Amadori ad-
in drinking water. Two non-diabetic groups were studied,ducts on proteins [13–15]. Although both AG and the
one receiving no treatment (non-diabetic control; N Amadorin pyridoxamine (PM) inhibited the chemical
13), the other receiving PM at 2 g/L in drinking watermodification of protein by ribose and glucose in vitro,
(non-diabetic  PM; N  12). The higher dose of PMonly PM was effective in inhibiting the formation of
in the PM-treated control group was designed to com-AGEs from Amadori adducts on glycated proteins, pre-
pensate, in part, for the lower water intake of non-dia-pared by anaerobic incubation with ribose or glucose.
betic, compared to diabetic animals. All animals wereThus, there is overlap in the AGE-inhibitory activity of
housed individually with a light dark cycle of 12 hoursthese compounds, with PM having a broader range of
each, and had free access to food and water. To maintaininhibitory activity, that is, inhibition of post-Amadori
body weight and to limit hyperglycemia, all diabetic ani-reactions. In a recent report [16] we showed that PM
mals were treated with 3 IU of ultralente insulin (Hu-was also an effective inhibitor of advanced lipoxidation
mulin U; Eli Lilly) three times per week in the afternoonreactions, inhibiting the modification of lysine residues in
(3 to 5 pm); the dose was increased to 5 IU after weekRNase and low-density lipoprotein (LDL) during metal-
15 to maintain glycemic control as the rats gained weight.catalyzed oxidation reactions, as well as the formation
of CML and CEL, malondialdehyde-lysine (MDA-Lys)
Glycemic controland hydroxynonenal-lysine (HNE-Lys). We report here
Glycemia was monitored monthly by measurement ofthat AGE/ALE inhibitor PM inhibits the development
plasma glucose and glycated hemoglobin. Non-fastingof early renal dysfunction, as measured by the increase
blood was obtained in the morning from the tail vein,in urinary albumin and plasma creatinine concentrations
using heparinized microhematocrit tubes, and plasmain the streptozotocin (STZ)-induced diabetic rat. We
recovered by centrifugation. Plasma glucose was mea-also made the unexpected observation that PM reduced
sured using the Trinder assay Kit: (Sigma # 315). Totalthe increase in hyperlipidemia and the alterations in re-
glycated hemoglobin (GlcHb) was measured on wholedox balance in the STZ-diabetic rat. Considering the
blood by boronate affinity chromatography (Sigma kitgrowing recognition of the importance of hyperlipidemia
and dyslipidemia in the development of both diabetic # 442-B).
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Measurement of drug levels in plasma and urine Necropsy and tissue sampling
Blood was drawn from anaesthetized (isofluorane) ratsPyridoxamine and AG concentrations in plasma were
by heart puncture and transferred into heparinized vacu-measured by reverse phase–high performance liquid
tainer tubes on ice. Rats were killed by over-anesthetiza-chromatography (RP-HPLC). PM was assayed as de-
tion, and liver and kidneys were removed, the kidneyscribed by Sampson and O’Connor [22], with excitation
decapsulated, and both organs rinsed in phosphate buf-and emission wavelengths of 293 nm 393 nm, respec-
fered saline, and weighed; sections were dissected andtively. AG was quantified at 380 nm as the 4-nitrobenzal-
fixed for electron and light microscopy. Abdominal skindehyde conjugate [23].
(2 cm2) also was removed, rinsed in phosphate buffered
Renal function saline (PBS) and stored at 70C. Blood was stored on
ice and separated into plasma and red blood cells (RBC)Progression of renal disease was assessed by monthly
within 30 minutes by centrifugation in a refrigeratedmeasurements of urinary albumin and plasma creatinine
benchtop centrifuge. Aliquots of plasma were stored atconcentrations. For urinary measurements, rats were
70C until time of analysis.housed in metabolic rat cages (Nalgene; Nalge Company,
Rochester, NY, USA) for 24 hours. Several drops of
Isolation and analysis of collagentoluene were added to the urine collection beaker to
The insoluble fraction of skin collagen was preparedinhibit microbial growth. Urinary albumin was quantified
by scraping the skin with a single-edged razor blade toby a competitive ELISA assay. Rabbit antiserum to rat
remove hair and adventitious tissue, followed by a seriesalbumin and horseradish peroxidase (HRP)-conjugated
of extractions with 0.5 mol/L NaCl, 0.5 mol/L aceticgoat anti-rabbit IgG were purchased from ICN Biomedi-
acid and chloroform/methanol (2:1 vol/vol), as describedcal Research Products (Costa Mesa, CA, USA). Briefly,
previously [26]. Fructoselysine (FL), a measure of thewells were coated with 50 ng of rat albumin (Sigma) in
extent of glycation of collagen, and the AGE/ALEs,0.1 mol/L sodium carbonate buffer, pH 10.4, overnight
CML and CEL, were assayed by isotope dilution, se-at 4C. In the competition step 100 L of standard or
lected ion monitoring gas chromatography–mass spec-urine sample was incubated with 100 L of rabbit anti-
trometry (SIM-GC/MS), and pentosidine by RP-HPLCrat albumin antiserum for three hours at room tempera-
[26]. Levels of these AGE/ALEs were normalized to theture on a microplate shaker. After washing, horseradish
lysine content of the collagen since lysine is a commonperoxidase-conjugated goat anti-rabbit IgG (200L) was
component of all of the compounds.applied for one hour at 25C with shaking, and the plate
The relative extent of cross-linking of collagen waswas developed with 200L of ABTS-reagent (2,2-azino-
estimated from the kinetics of digestion of the collagenbis(3-ethylbenzthiazoline-6-sulfonic acid) for 45 min-
by pepsin. Digestion of collagen (3 mg suspended in 7.5utes at room temperature. Absorbance was measured at
mL 0.5 mol/L acetic acid) was initiated by addition of405 nm.
pepsin [3 L of 1% (wt/vol) solution, yielding 20 gPlasma creatinine concentration was measured by the
pepsin/mL final concentration or 50 g pepsin/mg colla-
Jaffe´ picric acid procedure, using Sigma kit # 555-A.
gen], and samples were incubated at 37C in a water
Absorbance at 490 nm was measured before and after bath with shaking at 60 Hz. Aliquots (250 L) of the
addition of the acid reagent. In these and other clinical supernatant were removed at various times and mixed
assays, samples were diluted so that measurements were with an equal volume of concentrated HCl and hy-
within the range of the standard curve. None of the drolyzed for 24 hours at 110C. Percent digestion of
assays was subject to interference by aminoguanidine or collagen at each time point was calculated as percent
pyridoxamine. hydroxyproline released into supernatant, compared to
hydroxyproline in the supernatant at 24 hours when com-Plasma lipids and other metabolites
plete digestion of all samples was achieved, that is,1%
Total cholesterol and triglycerides were measured by residual collagen was present in the pellet fraction. Hy-
enzymatic, colorimetric, end-point assays using Sigma droxyproline was measured in acid hydrolysates of the
kits for total cholesterol (#352) and total triglycerides protein by the method of Stegemann and Stalder [27].
(#37, GPO Trinder). Free fatty acids were measured as The final hydrolysate diluted 10-fold in 0.5 mol/L acetic
copper complexes in organic solvent, as described by acid was analyzed directly for total Maillard-type fluo-
Noma et al [24]. Glycerol was measured by a spectromet- rescence (Ex  370 nm, Em  440 nm), and normalized
ric enzymatic assay using glycerol kinase and glycerol to the Hyp content of the solution.
3-phosphate dehydrogenase, as described by Bergman
Renal morphometry[25]. Lactate and pyruvate were measured spectrophoto-
metrically, using NADH/NAD linked assays (Sigma A sample from the right kidney of each rat was fixed
in 10% buffered formalin and embedded in JB-4. Five-Kits #826 and 726, respectively).
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Table 1. Body weights and metabolic control in various groups of animalsa
Final weightb Plasma glucose GlcHb Collagen glycation
N g mmol/L % mol FL/mol Lys
Non-diabetic control 13 28510.7 5.10.4 7.30.7 4.81.6
PM-treated control 12 26111.9c 5.00.3 7.30.4 5.01.7
Untreated diabetic 12 24824.9 26.72.1 15.80.6 23.83.4
PM-treated diabetic 12 21323.0d 26.02.9 15.41.2 21.12.8
AG-treated diabetic 13 22523.0d 25.34.0 14.41.6 21.54.0
a Data are means  SD. Measurements are shown for week 28 and are representative of results obtained throughout the study. Abbreviations are: GlcHb, glycated
hemoglobin; Fl, fructoselysine; Lys, lysine; PM, pyridoxamine; AG, aminoguanidine.
b Initial weights for all groups were 1788.4 g
c P  0.05 vs. untreated control rats
d P  0.05 vs. untreated diabetic rats
micrometer thick sections were cut and stained with To- ficiency associated with the decrease in body weight of
rats treated with AGE inhibitors. Mean water intakeluidine Blue. These sections were processed, as described
elsewhere, to determine glomerular volume [28]. A sec- for the untreated diabetic rats, measured at monthly
intervals between 14 and 28 weeks, was 235 mL/day;ond sample of kidney was cut into one-millimeter cubes,
fixed in 2.5% glutaraldehyde and embedded in PolyBed water intake was decreased to 185 and 145 mL/day in
PM- and AG-treated animals, respectively. Mean 24-812. Images were obtained with a JEOL 100CX electron
microscope (JEOL, Tokyo, Japan) and used to deter- hour urine volumes were 200, 155 and 125 mL/day in
these groups, respectively. Effects of drugs on food andmine fractional volume of mesangium per glomerulus
[29] and glomerular basement membrane (GBM) width water intake are being followed more closely in subse-
quent studies.[30]. Because of the costs involved and the focus on PM,
morphological studies were limited to diabetic and PM-
Metabolic controltreated diabetic rats.
Acute, intermediate and long term measures of gly-
Statistical analysis cemic control were obtained by monthly measurements
Statistical analyses were performed using SigmaStat of plasma glucose and glycated hemoglobin, and by mea-
for Windows V1.00 (SPSS, Inc., Chicago, IL, USA). P val- surement of glycated skin collagen at the end of the ex-
ues were calculated by non-parametric Mann-Whitney periment (Table 1). Mean plasma glucose levels (morn-
Rank Sum analysis. Correlation analyses were performed ing, non-fasting) in both groups of non-diabetic animals
by the Pearson Product Moment method. Unless indicated were 5 mmol/L for the duration of the study. In the
otherwise, all data are presented as mean  SD. diabetic groups, mean plasma glucose levels were 21
mmol/L at one week and stayed at that level during the
first eight weeks of the study. During the next several
RESULTS
weeks, plasma glucose levels rose gradually to nearly 30
Animal weights mmol/L in the diabetic groups. At week 15, the insulin
dose was adjusted from 3 to 5 IU every other day in allThe mean weight of diabetic animals was significantly
lower than that of non-diabetic animals (Table 1), how- diabetic groups, such that plasma glucose levels were
26 mmol/L or fivefold higher than the non-diabeticever, the insulin regimen was sufficient both to support
weight gain in the diabetic animals during the early stages animals throughout the remainder of the study. There
were no statistically significant differences in plasma glu-and to maintain their weight at the later stages of the
study. Mortality was less than 5% among diabetic ani- cose among any of the diabetic groups at any time point.
The increase in plasma glucose levels in the diabeticmals during the study. Control animals treated with PM
weighed 10% less than untreated controls (P  0.05). animals was accompanied by an increase in GlcHb. By
eight weeks, GlcHb reached a mean value of 16% inWith the exception of the weight difference, all other
parameters, including apparent redox imbalances, lipe- all diabetic groups, compared to 7.3% in the non-diabetic
animals (Table 1). Neither PM nor AG had an effect onmia, AGEs, etc., measured in PM-treated, non-diabetic
animals were statistically identical to those in untreated, glycemic control in diabetic animals, as measured by
either plasma glucose or GlcHb. Assuming slow turnovernon-diabetic controls. Diabetic animals consuming PM
or AG also weighed 10% less than the untreated dia- of insoluble skin collagen, glycation of this collagen
should reflect very long term, steady-state glycemic con-betic group (P  0.05); the weights of the PM- and
AG-treated diabetic animals were statistically identical trol. As shown in Table 1, the mean concentration of
FL in diabetic animals was 4.9-fold higher than FL in(Table 1). There was no evidence of any nutritional de-
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non-diabetic animals, compared to a 5.2-fold increase in
mean plasma glucose and 2.2-fold increase in GlcHb in
the diabetic animals. Thus, measurement of FL in colla-
gen provided a more sensitive and accurate index of the
increase in glycemia, than did GlcHb.
Drug concentrations in plasma and urine
Concentrations of PM and AG were measured in
morning plasma specimens during the 28th week of the
study. In non-diabetic animals receiving 2 g PM/L of
drinking water, the plasma PM concentration was 6.3 
2.1 mol/L. In polydypsic and polyuric diabetic animals
receiving 1 g PM/L in drinking water, the plasma PM
concentration was 106  17 mol/L, compared to ap-
proximately 5 mmol/L concentration of PM in their
drinking water and urine. The intent of the treatment
of the non-diabetic animal with a twofold higher concen-
tration of PM in their drinking water was to achieve
comparable levels of PM in plasma of both diabetic ani-
mals and non-diabetic controls, however the concentra-
tion of PM in plasma of control animals reached only
6% of that in diabetic animals. Urinary PM excretion Fig. 1. Effect of pyridoxamine (PM) and aminoguanidine (AG) on
development of nephropathy in streptozotocin (STZ)-diabetic rats.measured in 24-hour urine specimens from diabetic rats
Urine (24-hour samples) and blood were collected at 4-week intervalsat 23 weeks was 824 44 mol/day, while the PM intake for measurement of urinary albumin (A) and plasma creatinine (B)
estimated from water consumption was 801  22 mol/ concentrations. Symbols are: () untreated, non-diabetic control; ()
PM-treated, non-diabetic control; () diabetic control; () AG-treatedday (P 	 0.05), indicating that most of the PM was
diabetic; and () PM-treated diabetic rats. All diabetic groups vs. non-
excreted unchanged in urine. Although the molar con- diabetic controls in A and B, P
 0.001. For this and subsequent graphs:
a,b,c,d,eP  0.0001,  0.001,  0.01,  0.05, and NS vs. D; f,gP  0.01, P centration of PM was approximately half that of AG
0.05 vs. D  AG; hP 	 0.05 vs. C.in the drinking water of the diabetic rats (both were
administered at 1 g of the salt form/L), the mean concen-
tration of PM in diabetic rat plasma was approximately
20% greater than that of AG (87  10 mol/L; P 0.01 Dyslipidemia
vs. PM). This is consistent with pharmacokinetic studies At necropsy we observed that the plasma of untreated
indicating that the half-times for clearance of AG and diabetic animals was visibly more lipemic than that from
PM, administered by gavage, were approximately 30 control and PM- or AG-treated animals. Assays of
minutes and 1.5 hours, respectively (unpublished obser- plasma lipids (Fig. 2) documented a substantial increase
vations). in lipemia in untreated STZ-diabetic rats, and significant
correction of hyperlipidemia by both PM and AG. Tri-
Progression of renal disease
glycerides (Fig. 2A) increased to a mean of approxi-
Urinary albumin and plasma creatinine concentrations mately 700 mg/dL in diabetic rats, compared to 100
were used as indicators of renal function (Fig. 1). In mg/dL in non-diabetic controls, and were reduced 80 to
contrast to control or PM-treated non-diabetic animals, 60%, to means of 220 and 350 mg/dL by PM and AG,
albuminuria increased with time in all diabetic groups, respectively. Plasma cholesterol (Fig. 2B) was increased
with untreated diabetic animals showing the greatest in- by approximately 50%, and was normalized by PM and
crease. At 23 weeks and thereafter, all three diabetic partially corrected by AG.
groups were significantly different from one another, and
Redox imbalancesfrom non-diabetic controls, with respect to albuminuria
(Fig. 1A). Plasma creatinine values also began to rise Alterations in intermediary metabolism in diabetes
above normal after the 17th week (Fig. 1B). Both PM may result from glucose-induced redox imbalances (pseu-
and AG inhibited the rise in albuminuria and plasma dohypoxia) or decreased tissue oxygenation (true hypoxia)
creatinine, with PM being significantly more effective. [31–33]. These changes are reflected by a change in the
Urinary glucose concentration in diabetic rats was unaf- cytosolic ratio of NADH/NAD, which can be assessed
indirectly by measuring the ratio of lactate to pyruvatefected by drug treatment (not shown).
Degenhardt et al: Pyridoxamine treatment of diabetic rats944
Fig. 2. Effect of AG and PM on dyslipidemia
in STZ-diabetic rats. Plasma (28 weeks) was
analyzed for triglyceride (A), total cholesterol
(B). All diabetic groups vs. untreated, non-
diabetic controls: P 0.001. See footnote key
in legend to Figure 1.
in plasma. As shown in Figure 3, diabetic animals had diabetic animals these kinetics were complex, with a
significantly higher levels of both lactate and pyruvate burst of hydroxyproline-containing peptides released
in plasma, as well an increased ratio of lactate to pyr- during the first hour, followed by somewhat slower rates
uvate. Both PM and AG significantly corrected this ap- of digestion thereafter. In contrast, collagen from dia-
parent redox imbalance in the diabetic animals. betic animals was digested in a more linear fashion, and
at a slower rate throughout the 24-hour experiment. The
Chemical modification and cross-linking of collagen half time for digestion of skin collagen (50% release of
The effects of various drug treatments on AGE/ALE Hyp-peptides) increased approximately fivefold, from 90
concentrations in skin collagen at the end of the study minutes in control animals to 450 minutes in diabetic
are shown in Figure 4. AGE/ALEs and fluorescence in animals (Fig. 5B). PM and AG reduced the half time to
PM-treated non-diabetic animals were identical to those mean values of 350 and 300 minutes, respectively, that
in the untreated non-diabetic group (not shown). CML is, approximately 25 to 40% toward the control values.
concentrations (Fig. 4A) increased approximately 100%, Differences in kinetics of digestion of control and dia-
from 0.057  0.01 to 0.124  0.01 mmol/mol lysine in betic collagen were more impressive at shorter times,
non-diabetic controls versus untreated diabetic animals. such as at 20%, rather than 50% solubilization.
PM and AG treatment of diabetic animals limited the
Anatomical observationsincrease in CML to 0.092  0.02 and 0.10  0.02 mmol/
mol lysine, respectively, a 35 to 45% reduction toward As shown in Table 2, mean kidney and liver weights
the level in non-diabetic animals. CEL (Fig. 4B) in- were increased in diabetic rats, both in absolute terms
creased approximately 50%, from 0.018  0.004 mmol/ and as a fraction of total body mass. These changes in
mol lysine in control to 0.028  0.004 mmol/mol lysine tissue weight were partially reversed by both PM and
in diabetic animals. As with CML, both drugs limited AG. Occasional cysts were observed in kidneys of dia-
the accumulation of CEL, reducing it up to 50% toward betic animals, but were not increased in frequency in
levels in non-diabetic control animals. The fluorescent drug-treated groups. There was no evidence of an in-
AGE cross-link, pentosidine also increased approxi- crease in tumors in other major organs (heart, liver,
mately twofold, from 0.58 0.10mol/mol Lys in control intestines), nor of other unusual pathologies associated
to 1.1  0.16 mol/mol Lys in diabetic rats (Fig. 4C). with either PM or AG therapy. Characteristic changes
However, in contrast to CML and CEL, pentosidine in morphology were observed in the diabetic kidney (Ta-
concentrations were similar in all diabetic groups, that ble 3). PM caused a significant, partial correction of the
is, neither drug had a significant effect on the pentosidine increase in glomerular volume, but the effects of PM on
content of skin collagen. At the same time, both drugs GBM thickness and mesangial volume were not statisti-
caused approximately a 40% decrease in Maillard-type cally significant.
fluorescence in skin collagen of diabetic rats (Fig. 4D).
The unexpected results obtained for pentosidine are dis-
DISCUSSIONcussed later in this article.
These studies were designed to evaluate the efficacyIn addition to the increase in chemical modification,
of PM as an inhibitor of AGE formation and develop-collagen from diabetic animals typically shows a decrease
ment of renal disease in the STZ-diabetic rat. The STZ-in susceptibility to enzymatic digestion [34]. The kinetics
rat was chosen because of the reproducible developmentof pepsin digestion of skin collagen from the various
experimental groups are shown in Figure 5A. In non- of renal disease and several reports on the protective
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PM (and AG) were not anticipated in the original experi-
mental design. These factors have both complicated the
interpretation of the experimental results and raised
some interesting questions regarding the origin of renal
dysfunction in the STZ-diabetic rat.
Effect of PM on progression of renal disease in the
STZ-diabetic rat
Diabetic rats exhibited characteristic changes in renal
function and structure, including increasing urinary albu-
min and plasma creatinine concentrations, accompanied
by renal hypertrophy (Table 2), increased thickening of
GBM, and glomerular and mesangial volume expansion
(Table 3). Both PM and AG limited renal hypertrophy,
as measured by trends toward a reduction in absolute
kidney weight and significant effects on relative kidney
weight (Table 2). Although morphological changes in
the kidney were limited during the seven-month period
of the study, PM significantly inhibited the increase in
glomerular volume. Effects on the increase in mesangial
volume were encouraging, but not statistically significant.
There was only a 14%, but statistically significant in-
crease in basement membrane thickening in the diabetic
rats; this small increase was not significantly affected by
treatment with PM. Although effects of AG on renal
morphology were not measured in this study, studies on
AG treatment of the STZ-diabetic rat have also yielded
mixed results. One study reported inhibition of GBM
thickening in the Lewis rat [35], while there are two
reports that AG had no effect on GBM thickening in
Sprague-Dawley rats [36, 37]. The discordance between
the magnitudes of the structural and functional changes
in the diabetic kidney is puzzling; however, in a recent
study, anti-transforming growth factor- (anti-TGF-)
antibody inhibited renal morphological changes in the
db/db diabetic mouse, but had no effect on albuminuria
[38]. Because the AGE inhibitors do not correct all of the
structural and functional changes in the diabetic kidney,
they may be useful in combination with other renopro-
tective therapies, such as ACE inhibitors.
Fig. 3. Effect of AG and PM on redox state in STZ-diabetic rats.
Plasma (28 weeks) was analyzed for lactate (A) and pyruvate (B) con- Metabolic effects of AGE/ALE inhibitorscentrations. The ratio of lactate/pyruvate, an index of intracellular redox
status, is shown in (C ). See footnote key in legend to Figure 1. Although lipid lowering effects of AG in diabetic hu-
mans have been reported previously [39], the magnitude
of the effects of both PM and AG on plasma cholesterol
and triglycerides in the STZ-diabetic rats has not beeneffects of the AGE inhibitor AG against both AGE
noted previously. These changes could result from eitherformation and nephropathy in this model [10, 12; earlier
primary effects of the drugs on lipid metabolism or sec-work reviewed in 7]. While these studies were in prog-
ondary effects related AGE/ALE-inhibition. It is un-ress, we learned that PM was also an effective inhibitor
likely, however, that the metabolic effects are related toof formation of ALEs during lipid peroxidation reactions
the vitamin B6 activity of PM. PM and AG are structur-[16]. As well, we learned at the end of the study that,
ally unrelated compounds, and the fact that they producelike AG, PM exerted profound effects on hyperlipidemia
similar effects in diabetic animals is most consistent withand redox imbalances in the STZ-diabetic rat. The activ-
a mechanism of action based on their common nucleo-ity of PM as an ALE inhibitor and the complicating
effects of hyperlipidemia and its partial correction by philic character.
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Fig. 4. Effect of diabetes and drug treatment
on levels of advanced glycation end-products
(AGEs) and fluorescence in skin collagen.
Skin collagen was analyzed for concentrations
of CML (A), CEL (B) pentosidine (C ), and
fluorescence (D). All diabetic groups vs. un-
treated, non-diabetic control in A, B, C & D,
P  0.0001. See footnote key in legend to
Figure 1.
Hyperglycemia is known to induce shifts in intracellu- of diabetes. The AGE/ALEs, CML, CEL and pentosi-
dine, as well as Maillard-type fluorescence, were in-lar ratios of redox coenzymes, both in vitro and in vivo,
leading to a state of pseudohypoxia [31]. However, the creased approximately twofold in both skin collagen of
diabetic animals, compared to controls, after sevensignificant increase in lactate and the lactate to pyruvate
months of diabetes. At the doses of PM and AG tested,ratio in plasma of diabetic rats suggests true hypoxia
we observed an approximately 50% inhibition of thein major tissues in the body. Decreased perfusion and
increase in CML, CEL and fluorescence in skin collagenoxygenation of muscle and nerve in both humans and
of diabetic animals, supporting the activity of these com-animal models of diabetes [32, 33, 40–42] could be caused
pounds as AGE/ALE inhibitors in vivo. Although ourby AGE/ALE-dependent thickening and stiffening of
HPLC and GC/MS methods lacked the sensitivity forbasement membranes or loss of autoregulation in the
measurement of AGEs in isolated renal glomerular orperipheral vasculature. The resultant increase in anaero-
tubular collagen, immunohistochemical studies indicatebic metabolism of carbohydrates in the diabetic animals
that there is a significant decrease in CML or other AGE/suggests that aerobic metabolism of lipids might also be
ALEs in the kidney [12] and mesenteric vasculature [45]impaired, contributing, in part, to the hyperlipidemia in
of AG-treated versus untreated STZ-diabetic rats. AGthe diabetic rat. Studies on the kinetics of response to
also is known to inhibit the increase in cross-linking ofintervention therapy with AGE/ALE inhibitors should
collagen in diabetic rats, as measured by changes in tailprovide insight into whether the drugs acutely and di-
tendon stability [46] or protease digestibility of aorticrectly affect metabolic pathways of lipid metabolism or
[6], renal [47], or tail tendon [48] collagen. In the presentexert their effects secondarily through inhibition of long-
studies, the half-time for solubilization of skin collagenterm structural changes in the vascular wall.
by pepsin was increased about fourfold in diabetic, com-
Effect of PM on AGE/ALEs in collagen pared to control rats, and was decreased by 25 to 40%
toward normal in diabetic rats treated with PM or AG.As in previous studies with AG and other AGE inhibi-
tors [6–12], PM had no effect on the increase in glycemia The lack of an effect of either PM or AG on pentosidine,
despite significant effects on other AGE/ALEs, fluores-or glycation of hemoglobin or collagen in the diabetic
rats. Like AG [43, 44], PM also did not appear to affect cence and pepsin digestibility, suggests that other fluo-
rescent cross-links (such as vesperlysines, crosslines andpolyol pathway activity or osmotically-induced oxidative
stress in the lens of diabetic rats, since all diabetic animals fluorolink) or non-fluorescent cross-links (such as dily-
sine imidazolium salts formed from glyoxal and meth-developed bilateral sugar cataracts after 8 to 12 weeks
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Table 2. Effects of diabetes and drug treatment
on liver and kidney weight
Kidney Kidney Liver Liver
g g/100 g g g/100 g
Control 0.840.04 0.320.02 7.960.5 3.370.22
Untreated diabetic 1.530.21 0.730.23 16.73.4 7.030.94
Diabetic  PM 1.250.30 0.590.05 12.82.1 6.000.59
Diabetic  AG 1.310.18 0.590.07 14.02.6 6.200.99
P value:
D  PM vs. D 	0.05 0.001 0.0025 0.002
P value:
D  AG vs. D 	0.05 0.002 0.05 	0.05
Abbreviations are: PM, pyridoxamine; AG, aminoguanidine; D, diabetic rats.
Table 3. Effect of diabetes and drug treatment on renal
morphometry
Glomerular Mesangial
volume volume
GBM width
 10 6 lm3 nm
Non-diabetic control 1.300.10a 0.250.05a 20114.9a
Diabetic control 2.080.27 0.520.22 22919.4
Diabetic  PM 1.680.08b 0.460.12 22525.1
a P  0.001 vs. untreated diabetic animals
b P  0.025 vs. untreated diabetic animals
dine appears to be derived exclusively from carbohy-
drates [49]. The failure of PM to inhibit the increase in
pentosidine in diabetic skin collagen was unexpected,
but is consistent with the observation that PM is also
less effective in inhibiting formation of pentosidine, com-
pared to CML, from glycated protein in vitro (personal
communication; Voziyan PA and Hudson BG, Univer-
sity of Kansas Medical Center). Higher concentrations
of PM may be required for efficient trapping of interme-
diates in pentosidine formation, while the failure of AG
to inhibit the increase in pentosidine may be attributed,Fig. 5. Influence of diabetes and drug-treatment on cross-linking (pro-
at least in part, to the fact that AG is not an effective inteolytic digestibility) of rat skin collagen. Collagen was digested with
pepsin and Hyp release in the supernatant was measured as a function vitro inhibitor of the formation of AGEs from Amadori-
of time of digestion. (A) Kinetics of digestion: () untreated, non- modified proteins [13, 14]. AG inhibition of pentosidinediabetic control; () diabetic control; () AG-treated diabetic; and
formation in numerous in vitro studies may be attributed() PM-treated diabetic rats. (B) Time for 50% digestion. See footnote
key in legend to Figure 1. to its chelating activity at the high concentrations of AG
commonly used in in vitro experiments [50] [Price et al,
J Biol Chem (in press)]. Although CML and CEL may
ylglyoxal (GOLD and MOLD) [1, 2]) may be more sensi- be derived from lipids, the relative increases in CML,
tive to inhibition by PM and AG. In general, despite CEL and pentosidine are similar in diabetic compared to
differences in their mechanism of action as AGE inhibi- control rats, consistent with their origin from a common
tors in vitro, that is, PM, but not AG, inhibits post- precursor and pathway. The relative levels of CML and
Amadori reactions, the two drugs had comparable effects pentosidine in diabetic skin collagen are also comparable
on AGE/ALE formation, fluorescence and cross-linking to their relative yields during modification of collagen
of skin collagen of diabetic rats, including their failure by glucose or ribose in vitro, that is, 50- to 100-fold higher
to inhibit the increase in pentosidine formation.
concentration of CML, compared to pentosidine [51–53].
Origin of AGE/ALEs: Carbohydrates or lipids? Thus, it is reasonable to propose that all three of these
products, as well as the increase in fluorescence andCarbohydrates. Although the exact source and route
of formation of pentosidine in vivo is uncertain, pentosi- cross-linking of diabetic collagen, are derived from gly-
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coxidation reactions. It is possible that ascorbate, which onset of hyperglycemia. This time-course for develop-
ment of hyperlipidemia is consistent with an effect re-is a common precursor of CML, CEL and pentosidine
[51, 54], rather than glucose, may be the common carbo- sulting from slow, AGE/ALE-mediated changes in vas-
cular architecture. It also is possible that the decreasehydrate source of these compounds in the diabetic ani-
mals. Notably, ascorbate is the more readily oxidized, in AGE/ALEs in the STZ-diabetic rat might be attrib-
uted to direct effects of PM (and AG) on lipid metabo-compared to glucose and has an important supporting
role as an inhibitor of lipid peroxidation chain reactions lism by some mechanism independent of their ALE in-
hibitory activity. Although we cannot exclude metabolicby maintaining vitamin E in the reduced state [55]. Its
oxidation product, dehydroascorbate, is also a potent effects, independent of AGE/ALE inhibition, this seems
less likely because the two compounds, PM and AG,source of both CML and pentosidine [51, 56]. Significant
alterations in ascorbate homeostasis occur commonly in are significantly different in structure and therefore less
likely to have identical regulatory effects on metabolicdiabetes [57], including the STZ-diabetic rat model [58].
Overall, despite the lack of an effect of either PM or pathways.
AG on the increase in pentosidine in skin collagen, our
results are reasonably consistent with a role for carbohy-
CONCLUSION
drate, probably ascorbate, as the primary source of the
We have demonstrated that the AGE/ALE inhibitors,increased chemical modification of proteins in the STZ-
PM and AG, retard the decline in renal function, sub-diabetic rat.
stantially reverse dyslipidemia and apparent redox im-Lipids. Dyslipidemia and hyperlipidemia are recog-
balances, and inhibit the chemical modification andnized as independent risk factors for development of dia-
cross-linking of tissue proteins in the STZ-diabetic rat.betic nephropathy [59, 60], and also are associated with
Our results indicate a complex interplay between thenephrotic syndromes, independent of diabetes [61, 62].
altered chemistry and biochemistry of carbohydrates,We have observed recently that CML, CEL and, unex-
lipids and ascorbate in the development of diabetic com-pectedly, pentosidine are increased in skin collagen of
plications, but are consistent with the proposed mecha-the non-diabetic (normoglycemic) Zucker fa/fa rat, and
nism of action of PM and AG as AGE/ALE inhibitors.that PM also inhibits the development of nephropathy,
PM achieved slightly higher plasma concentrations thanreduces the hyperlipidemia and inhibits the increase in
AG although it was administered at 50% the AG dose:CML and CEL, as well as pentosidine, in skin collagen
both drugs were administered at 1 g/L, equivalent toof these animals (manuscript in preparation). Since fa/
4 mmol/L PM and 8 mmol/L AG, while mean plasmafa rats are normoglycemic, glucose is an unlikely source
concentrations were 106 mmol/L PM and 87 mmol/Lof the increase in these compounds. Thus, the increase
AG. The higher concentration of PM at lower dosagein chemical modification of proteins could be entirely
may be attributed to differences in bioavailability and/orattributable to ascorbate and/or lipids. A sequence of
pharmacokinetics. Although PM was present at 20%events might be considered in which AGE/ALE-depen-
higher concentration in plasma, it was substantially moredent changes in collagen and basement membranes in
effective than AG in retarding the development of renalthe microvasculature may limit tissue perfusion, causing
disease, hyperlipidemia and redox changes in the dia-hypoxia, limiting oxidative metabolism of lipids, and
betic rat. Despite these differences, the two drugs hadleading to secondary hyperlipidemia. Intervention in this
similar effects on inhibition of AGE/ALE formation andsequence of events by AGE/ALE inhibitors might cor-
collagen cross-linking, including their failure to inhibitrect the vascular changes, leading eventually to increased
pentosidine formation, so that their mechanism(s) ofoxidative metabolism of lipids and a decrease in hyper-
action must involve more than inhibition of AGE/ALElipidemia. At this time, however, we cannot exclude the
formation alone. The better bioavailability of PM andpossibility that the hyperlipidemia is entirely secondary
its low toxicity (5 to 7.5 g/kg oral LD50 in rodents) [63],to alterations in renal function (proteinuria), and that
combined with its more pronounced effects on renalprotection of renal function by unknown mechanisms
disease, hyperlipidemia and metabolic changes, com-may lead to the decrease in lipemia in PM-treated rats.
pared to AG, suggest that PM may be useful for clinicalAlthough we did not address the temporal relationship
treatment of a wide range of diabetic complications, in-between dyslipidemia, renal dysfunction and AGE/ALE
cluding vascular disease and neuropathy. Future studiesformation in the present study, the fractional decrease
on progression of disease in normolipidemic, diabeticin AGE/ALEs in skin collagen was comparable to, and
animals and in nephrotic, non-diabetic animals, on lipid-correlated with, the fractional decrease in lipemia in the
lowering agents without AGE/ALE inhibitory activity,PM-treated diabetic rats (Fig. 2 vs. Fig. 4). In other work
and quantification of PM adducts in urine of hyperglyce-in progress, we have observed that the dyslipidemia de-
mic and hyperlipidemic animals should lead to a bettervelops slowly in the STZ-diabetic rat, with a half-time
of approximately ten weeks, in contrast to the immediate understanding of the major chemical and biochemical
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